Clinical Research
Clinical Research
Clinical research in Central and Eastern Europe
Pharmaceutical development calls for patience and stamina. It takes around twelve years at a cost of around 1 billion euros from the development of an active substance to its launch as a new drug.
Years of experience and comprehensive know-how
The approval of a new drug is preceded by clinical trials. Knowledge of the effectiveness and safety of a new substance is acquired in four phases. Drugs already on the market are also regularly checked to ensure patient safety.
The Boehringer Ingelheim Regional Center Vienna has years of experience and comprehensive know-how in clinical research in the region. In the last few years in particular the number of trials and patients has developed dynamically. Alongside North America and Asia, the area covered by the Boehringer Ingelheim RCV is one of the most research-intensive regions in the world. The RCV is also responsible for approval procedures, drug safety, and technical product support in the countries it supervises.
-
Clinical Trial
In compliance with our Policy on Transparency and Publication of Clinical Study Data, Boehringer Ingelheim is committed to disclosing all study results independent of outcome. Responsible sharing of de-identified clinical study data and redacted clinical documents are reported.